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In response to intracellular pathogens, CD8+ T cells are ac-
tivated to proliferate and differentiate into a heterogeneous 
population of effector T cells, which are armed to eliminate 
infected cells. After pathogen clearance, the majority of ef-
fector CD8+ T cells die; however, a subset survives and dif-
ferentiates to long-lived memory T cells. Should reinfection 
occur, these memory cells undergo rapid expansion and 
redifferentiation into effector cells, providing superior pro-
tection compared with naive T cells and protecting the host 
for decades in many cases (Harty and Badovinac, 2008). The 
ability to selectively induce T cell memory would provide 
novel methods for provoking protective immunity and in-
form vaccine strategies.
Identification of effector and memory precursor CD8+ 
T cells within the effector population is facilitated by their dis-
tinct expression of several surface receptors. Both subsets ex-
press high levels of CD44, whereas IL-7-receptor-α (CD127) 
is selectively up-regulated during the transition to long-lived 
memory cells (Kaech et al., 2003). Killer cell lectin-like re-
ceptor G1 (KLRG1) expression is inversely correlated with 
CD127 expression (Joshi et al., 2007) and identifies, in both 
mice and humans, a subset of terminally differentiated ef-
fector cells that possess limited proliferative potential and a 
shorter lifespan (Voehringer et al., 2002; Joshi et al., 2007). 
ZEB2 is a multi-zinc-finger transcription factor known to play a significant role in early neurogenesis and in epithelial-mes-
enchymal transition–dependent tumor metastasis. Although the function of ZEB2 in T lymphocytes is unknown, activity of the 
closely related family member ZEB1 has been implicated in lymphocyte development. Here, we find that ZEB2 expression is 
up-regulated by activated T cells, specifically in the KLRG1hi effector CD8+ T cell subset. Loss of ZEB2 expression results in a 
significant loss of antigen-specific CD8+ T cells after primary and secondary infection with a severe impairment in the gener-
ation of the KLRG1hi effector memory cell population. We show that ZEB2, which can bind DNA at tandem, consensus E-box 
sites, regulates gene expression of several E-protein targets and may directly repress Il7r and Il2 in CD8+ T cells responding to 
infection. Furthermore, we find that T-bet binds to highly conserved T-box sites in the Zeb2 gene and that T-bet and ZEB2 
regulate similar gene expression programs in effector T cells, suggesting that T-bet acts upstream and through regulation of 
ZEB2. Collectively, we place ZEB2 in a larger transcriptional network that is responsible for the balance between terminal 
differentiation and formation of memory CD8+ T cells.
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Thus, differential expression of CD127 and KLRG1 identi-
fies two populations of T cells during the peak of an infection: 
KLRG1hiCD127lo cells that consist of shorter-lived effector 
and effector memory cells and KLRG1loCD127hi effector 
cells that include the long-lived memory precursors (Kaech 
and Wherry, 2007; Kallies, 2008). Notably, both populations 
undergo contraction as the infection is cleared; however, the 
KLRG1hi subset continues to contract over the months after 
antigen exposure, whereas the CD127hi subset provides stable, 
persistent memory (Sarkar et al., 2008).
The differentiation of CD8+ T cells into KLRG1hi short-
er-lived effector cells in response to antigen is accompanied 
by dramatic changes in gene expression (Kaech et al., 2002; 
Goldrath et al., 2004). Although much is known about how 
antigen exposure and inflammatory signals impact this dif-
ferentiation, the specific transcriptional pathways that control 
terminal differentiation versus memory formation have yet to 
be fully elucidated. It is now clear that multiple transcription 
factors work in concert during differentiation of CD8+ effec-
tor T cells to instruct terminal differentiation versus memory 
cell fates. These factors include, but are not limited to, T-bet, 
Blimp-1, Id2, and STAT4 promoting the formation of KL-
RG1hiCD8+ effector and effector memory T cells and Eome-
sodermin, Bcl-6, Id3, STAT3, FOXO1, and TCF1 favoring 
differentiation of CD127hi effector and memory precursor 
CD8+ T cells (Kaech and Cui, 2012). Many of these factors 
are expressed by both KLRG1hi and CD127hi effector T cells, 
albeit at higher levels in the subset that their expression sup-
ports. Thus, it is not yet clear how these factors assemble into 
a network that allows bifurcation into distinct fates.
Analysis of the transcriptional network responsible for 
CD8+ T cell activation and differentiation led to the iden-
tification of transcriptional regulators, including ZEB2 (also 
known as Zfhx1b and Sip1) not previously associated with T 
cell immunity (Joshi et al., 2007; Wirth et al., 2010; Best et al., 
2013). ZEB2 is a two-handed zinc-finger transcription factor 
and one of two members of the ZEB family in vertebrates; 
ZEB1 and -2 bind DNA at tandem, separated (Remacle et al., 
1999) consensus E-box sites (Sekido et al., 1994) and may be 
in direct competition for E-protein–binding sites. ZEB2 can 
also mediate transcriptional repression via cooperation with 
activated Smads or through recruitment of the corepressor 
CtBP as well as histone deacetylase complexes, particularly 
NuRD (Verschueren et al., 1999; Postigo and Dean, 1999b; 
van Grunsven et al., 2007; Verstappen et al., 2008).
The role of ZEB proteins in mature T cell function 
has not previously been investigated. However, Goossens 
et al. (2015) recently found that ZEB2 drives immature T 
cell lymphoblastic leukemia in humans and mice, and in the 
mouse model this is caused by enhanced leukemia initiation 
potential and induction of CD127 expression. Additionally, 
ZEB1, likely through repression of E-box–containing genes 
such as CD4, IL-2, GATA-3, and α4-integrin, plays a crucial 
role in early T cell development (Williams et al., 1991; Hi-
gashi et al., 1997; Brabletz et al., 1999; Grégoire and Roméo, 
1999; Postigo and Dean, 1999a). Here we investigate a role 
for ZEB2 in the differentiation of CD8+ T cells in vivo. We 
show that ZEB2 is necessary for the formation of KLRG1hi 
effector cells and that ZEB2 is directly regulated by and acts 
downstream of the transcription factor T-bet to repress the 
memory gene expression program and support terminal dif-
ferentiation of effector CD8+ T cells.
RES ULTS
The transcriptional repressor ZEB2 is up-regulated by 
KLRG1hi effector CD8+ T cells
Through analysis of differential gene expression by CD8+ T 
cells over the course of an immune response, several poten-
tially novel regulators of transcription in CD8+ T cells were 
identified (Best et al., 2013). One transcription factor of par-
ticular interest was ZEB2, whose homologous family mem-
ber, ZEB1, was shown to be important for the formation of 
early thymic precursors (Higashi et al., 1997; Postigo and 
Dean, 1999a). We found that Zeb2 mRNA was coregulated 
with genes involved in differentiation of shorter-lived effec-
tor cells, including Tbx21 (encoding T-bet), Klrg1 (Fig. 1 A), 
and Id2 (not depicted). Notably, our previous immune sys-
tem–wide analysis of gene expression patterns identified 
ZEB2 as a putative regulator of expression of key molecules 
(Best et al., 2013). Zeb2 mRNA was expressed at low lev-
els in naive CD8+ T cells but was substantially increased in 
CD8+ T cells responding to lymphocytic choriomeningi-
tis virus (LCMV) infection, correlating with the expansion 
of KLRG1hiCD8+ T cells (Fig. 1 B). Indeed, Zeb2 mRNA 
was expressed at >30-fold greater levels in the KLRG1hi 
compared with KLRG1lo effector CD8+ T cell population. 
In contrast, ZEB1 was not dynamically regulated in T cells 
responding to infection (Best et al., 2013). We also found 
that Zeb2 mRNA expression was considerably decreased in 
Id2-deficient T cells, which fail to generate KLRG1hi ter-
minally differentiated effector CD8+ T cells (Cannarile et 
al., 2006; Knell et al., 2013; Masson et al., 2013), compared 
with WT antigen-specific T cells (not depicted). Despite ex-
tensive efforts with available reagents, we were not able to 
successfully evaluate mouse ZEB2 protein levels. Both Id2 
and ZEB2 can function by attenuating E-protein activity, 
by direct binding to E-protein transcription factors and via 
competitive binding to E-box sites, respectively. Thus, we 
considered the possibility that ZEB2 acts as a second tran-
scriptional regulator, alongside Id2, that attenuates E-pro-
tein activity and is important for the fate decisions leading 
to the generation of KLRG1hi effector CD8+ T cells.
Impaired responses to infection by 
ZEB2-deficient CD8+ T cells
We next examined ZEB2-deficient CD8+ T cells over the 
course of infection. Mice bearing floxed alleles of Zeb2 were 
backcrossed to the C57BL/6 background and then to a CD4-
driven cre recombinase transgenic line to induce deletion 
in T cells (Sawada et al., 1994; Higashi et al., 2002). ZEB2 
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deficiency did not affect the phenotype of the naive T cell 
compartment (not depicted). We infected WT mice and mice 
lacking T cell–specific expression of ZEB2 with the Arm-
strong strain of LCMV and monitored CD8+ T cells specific 
for an epitope of LCMV using MHC class I-Db tetramers 
loaded with the gp33 peptide (Fig. 1 C). A significantly lower 
frequency of LCMV-specific CD8+ T cells was observed for 
ZEB2-deficient compared with WT mice at the peak and 
during contraction of the response. To rule out additional 
immune defects confounding the CD8+ T cell response, we 
generated ZEB2-deficient P14 TCR transgenic CD8+ T cells 
that recognized the same LCMV epitope, which were then 
adoptively transferred to naive recipients and distinguished 
from host cells by congenic CD45 expression. The frequency 
of ZEB2-deficient P14 TCR transgenic cells transferred 
alone or mixed with WT P14 cells was monitored in the 
blood of recipients after infection with LCMV (Fig. 1, D and 
E) or Listeria monocytogenes (Lm) expressing the LCMV 
peptide gp33 (Lm-gp33; not depicted). In all experimental 
settings, we observed a significantly impaired accumulation of 
ZEB2-deficient antigen-specific cells in response to infection 
compared with WT CD8+ T cells, showing a cell-intrinsic 
role for ZEB2 in the expansion of CD8+ antigen-specific ef-
fector T cell population.
In mice, ZEB2 has been shown to be important in 
regulating directed migration (Van de Putte et al., 2003; 
Goossens et al., 2011; van den Berghe et al., 2013), raising 
the question of whether this defect in accumulation in the 
blood and spleen could be the result of differential traf-
ficking of ZEB2-deficient cells. Alternatively, ZEB2 may be 
acting to promote cell survival (much like Id2 [Cannarile 
et al., 2006]) or in the control of proliferation. First, we ex-
amined the possibility that ZEB2-deficient cells were accu-
mulating in other tissues; recipients receiving a co-transfer 
of WT and ZEB2-deficient P14 CD8+ T cells were infected 
with LCMV (Fig. 1 E, right), and antigen-specific cells in 
the spleen, lymph nodes, liver, and lung were assessed at 
the peak of infection. Defects in accumulation were ob-
served for ZEB2-deficient compared with WT CD8+ T 
cells in all tissues examined, suggesting that ZEB2-deficient 
CD8+ T cells were not sequestered outside of the second-
ary lymphoid organs. Next, to discern potential defects in 
proliferation and survival by ZEB2-deficient cells during 
infection, we monitored incorporation of BrdU or An-
nexin V staining, respectively, in antigen-specific CD8+ 
T cells recovered from the spleen after LCMV infection 
(Fig.  1  F). We did not find notable differences between 
ZEB2-deficient and WT cells.
Figure 1. ZEB2 deficiency results in a re-
duced CD8+ T cell response. (A) Microarray 
analysis using Gene 1.0 ST array was per-
formed on OT-I T cells sorted on the indicated 
days after Lm-OVA infection. (B) Total P14 cells 
on the indicated days (left) or KLRG1hi and KL-
RG1lo P14 populations on day 14 after LCMV 
infection (right) were sorted, and ZEB2 expres-
sion levels were determined by qPCR. Expres-
sion is normalized to day 5 after infection or 
the KLRG1lo population, respectively. Zeb2+/+ 
and Zeb2−/− T cell kinetics were monitored 
after LCMV infection. (C–E) The frequency of 
endogenous CD8+ tetramer+ cells (C) or con-
genically marked P14 cells from single (D) 
or mixed transfers (E) on the indicated days 
of infection is shown. In mixed transfer re-
cipients, the percentage of P14 cells of total 
CD8+ T cells in the spleen, lymph node (LN), 
liver, and lung was analyzed on day 8 of in-
fection. (F) For mixed transfers, proliferation of 
P14 cells in the spleen was assessed by BrdU 
incorporation on days 5 and 6 of infection 
and Annexin V staining in 7AAD− P14 cells 
on day 5 of infection. Unstained BrdU control 
is displayed in gray. Numbers in histograms 
indicate the percentage of Annexin V+7AAD− 
P14 cells of a representative mouse. Data are 
from three (A) or two to five (B–D) indepen-
dent experiments with n = 2–6. Mean ± SEM 
is shown. Unpaired, two-tailed Student’s t test 
was performed to determine significance. *, P 
≤ 0.05; ***, P < 0.001.
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Loss of KLRG1hi effector CD8+ T cells with ZEB2 deficiency
We next examined the phenotype of ZEB2-deficient cells 
over the course of the immune response. Equal numbers of 
Zeb2+/+ and Zeb2−/− P14 CD8+ T cells were transferred into 
congenically distinct naive hosts that were then infected with 
LCMV. Throughout infection, the frequency and absolute 
number of KLRG1hiCD127loCD8+ T cells lacking ZEB2 
were reduced compared with WT CD8+ T cells (Fig.  2, A 
and B). Conversely, the frequency of the KLRG1loCD127hi 
longer-lived, memory precursor CD8+ T cell population was 
significantly increased. However, when the absolute num-
bers of the KLRG1loCD127hi subset were calculated, con-
sistently significant differences were not observed between 
Zeb2−/− and Zeb2+/+ populations, showing that the increase 
in frequency of this population was caused by a loss of the 
KLRG1hi subset and not by the generation of more memory 
cells (Fig. 2, B and C). Infection with a different pathogen, 
Lm-gp33, yielded comparable results (not depicted).
A more in-depth examination of the cell surface phe-
notype of ZEB2-deficient CD8+ T cells revealed that the 
majority of Zeb2−/− cells were KLRG1loCD127hi; they also 
displayed expression of additional characteristic long-lived 
CD8+ T cell memory markers (Fig. 2 D). Although the CD44 
activation marker appears unaffected, CD8+ T cells lacking 
ZEB2 were predominately CD43hi and CD27hi, which corre-
sponds to T cell populations with increased memory potential 
and is consistent with the enhanced frequency of the CD127hi 
population (Hikono et al., 2006). Interestingly, CD27 has 
been shown to define a population of CD8+ T cells that con-
tain central and effector memory T cell subsets (Olson et al., 
2013). High levels of CXCR3, a marker suggested to predict 
recall ability of memory CD8+ T cells (Hikono et al., 2007), 
was also noted on ZEB2-deficient CD8+ T cells throughout 
the course of infection. Thus, ZEB2-deficient effector CD8+ 
T cells differentiate into phenotypically normal memory pre-
cursor populations but form ∼60-fold fewer KLRG1hi termi-
nally differentiated CD8+ T cells in the contraction phase of 
the immune response (Fig. 2 and not depicted).
Similarly, cytokine production by Zeb2−/− CD8+ T 
cells during the immune response was consistent with typi-
cal function of the memory precursor populations. Lympho-
cytes were harvested and restimulated with gp-33 peptide, 
and levels of effector cytokines IFN-γ and IL-2 were assessed 
by flow cytometry. No difference in IFN-γ production was 
observed; however, a significant increase in the frequency 
of IL-2–producing cells was measured in the responding 
Zeb2−/− CD8+ T cells as compared with WT controls. This 
increase correlates with the loss of the KLRG1hi terminally 
differentiated effector CD8+ T cell population known to 
produce less IL-2 during infection (Fig. 2, E and F; Sarkar 
et al., 2008). These data provide phenotypic and functional 
evidence that ZEB2 plays a role in balancing the formation 
of KLRG1hi shorter-lived effector versus the CD127hi long-
lived memory cells, during infection, with ZEB2 promoting 
the formation or accumulation of KLRG1hi effector cells.
Impaired secondary response by ZEB2-
deficient memory CD8+ T cells
Given that ZEB2 deficiency leads to a higher percentage of 
KLRG1loCD127hi memory precursor CD8+ T cells during 
a primary response to infection, it might be expected that a 
secondary encounter of antigen would induce a more robust 
memory recall response. Alternatively, ZEB2-deficient cells 
could generate a secondary effector population with simi-
lar defects observed in the primary response. To address this, 
Zeb2+/+ and Zeb2−/− mice were initially infected with ve-
sicular stomatitis virus (VSV)–OVA and then reinfected with 
Lm-OVA 30 d later. MHC class I-Kb–OVAp tetramer stain-
ing was used to detect antigen-specific cells in the blood over 
the course of the secondary infection. Despite the overrep-
resentation of memory precursor cells in the ZEB2-deficient 
primary response, the defect in expansion was not rescued in 
the secondary response (Fig. 3 A, left). Similar kinetics were 
also observed when Zeb2+/+ and Zeb2−/− P14 cells were 
co-transferred to congenically distinct hosts that were first 
infected with Lm-gp33 and then subsequently infected with 
LCMV (Fig.  3  A, right). In both secondary infections, we 
observed impaired accumulation of KLRG1hiCD127lo termi-
nally differentiated effector CD8+ T cells (Fig. 3, B and C); 
however, in contrast to the primary response, we find that 
antigen-specific CD8+ T cells form an intermediate KL-
RG1hiCD127hi population. We observed a significant reduc-
tion in the frequency of KLRG1hiCD127lo cells generated 
by ZEB2-deficient compared with WT effector cells with a 
corresponding significant increase in KLRG1hiCD127hi and 
KLRG1loCD127hi populations, suggesting that ZEB2 may be 
involved in the down-regulation of CD127 rather than the 
up-regulation of KLRG1 by effector cells. This observation 
fits with the published data showing that KLRG1 is not es-
sential for the generation of terminally differentiated effector 
CD8+ T cells (Gründemann et al., 2010), whereas CD127 is 
necessary but not sufficient for memory precursor formation 
(Hand et al., 2007; Haring et al., 2008).
ZEB2 deficiency favors expression of 
memory-associated genes
To gain insight into potential downstream targets of ZEB2, 
we looked for global gene expression differences between 
Zeb2+/+ and Zeb2−/− CD8+ effector T cells on day 6 after 
LCMV infection, before the dramatic differences in subset 
distribution were observed. Strikingly, relatively few genes 
were differentially expressed between the two populations on 
day 6 of infection (Fig. 4 A and Table S1). However, Tcf7 
and Il7r both elevated in memory subsets were significantly 
higher in the Zeb2−/− cells, whereas effector-associated genes 
Zeb2, Gzma, and Klrg1 were all increased in WT cells.
In partnership with the Immunological Genome (ImmGen) 
Project, we previously examined the transcriptional programs 
initiated in CD8+ T cells during the response to in vivo infec-
tion. We grouped genes displaying differential gene expression 
into 10 unbiased clusters based on their kinetic patterns of 
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Figure 2. Lack of ZEB2 leads to a selective loss of terminally differentiated shorter-lived effector CD8+ T cells. (A) Co-transferred Zeb2+/+ and 
Zeb2−/− P14 T cells were analyzed on the indicated days after LCMV infection for KLRG1 and CD127 expression. Numbers indicate the percentage of the 
population in total P14 cells from a representative mouse. (B) Quantification of the frequency and total numbers of P14 populations represented in A on 
day 8 after LCMV infection. (C) Kinetics of the total KLRG1loCD127hiCD8+ T cell population over the LCMV infection. (D) Expression of surface markers on 
Zeb2+/+ and Zeb2−/− P14 cells on the indicated days after LCMV infection. (E) Intracellular cytokine staining after gp33 peptide restimulation on day 10 of 
LCMV infection. Numbers indicate the frequency for each quadrant from a representative mouse. (F) Quantification of IFNγ+ and IFNγ+IL2+ P14 cells. Data 
are representative of two to three independent experiments with n = 2–3. Mean ± SEM is shown. Unpaired, two-tailed Student’s t test was performed to 
determine significance. **, P < 0.01; ***, P < 0.001.
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expression and predicted the biological function most likely 
associated with each cluster (Best et al., 2013). In Fig. 4 B, 
we highlighted those clusters with the genes differentially 
expressed between Zeb2+/+ and Zeb2−/− CD8+ T cells that 
were identified above (Fig. 4 A and Table S1). Interestingly, 
the genes involved with preparation for cell cycle (cluster II) 
and cell cycle and division (cluster III) appeared to be more 
highly expressed in ZEB2 WT than ZEB2-deficient CD8+ 
T cells on day 6 of infection. This suggests that Zeb2−/− cells 
may have defects associated with initiation of proliferation 
at early time points, which could account for the defect in 
clonal expansion. Notably, cluster II is enriched in KLRG1lo 
and CD127hi populations (not depicted; Best et al., 2013), 
showing that differential gene expression in the Zeb2−/− ver-
sus Zeb2+/+ comparison is not the result of minor skewing of 
subset distribution. In addition, we found that genes associ-
ated with the naive and late memory cells (cluster IV) and the 
memory precursor cells (cluster VII) were expressed at higher 
levels by Zeb2−/− compared with Zeb2+/+ CD8+ T cells, in 
spite of the fact that the differences in T cell subset composi-
tion were not significantly developed at this same time point. 
These data are consistent with the fact that ZEB2 deficiency 
ultimately leads to a smaller KLRG1hi effector population, 
favoring the generation of the CD127hi long-lived mem-
ory subset, and raises the possibility that ZEB2 represses the 
memory gene expression program.
As ZEB2 shares a DNA-binding motif with E-proteins, 
we used previously published chromatin immunoprecipita-
Figure 3. ZEB2 is necessary for the down-regulation of CD127 
during a secondary response to pathogen. Endogenous CD8+te-
tramer+ cells in the PBL were analyzed in mice primarily infected with 
VSV-OVA, followed 30 d later with Lm-OVA (left). Co-transferred Zeb2+/+ 
and Zeb2−/− P14 T cells in the PBL were assessed in mice primarily in-
fected with Lm-gp33, followed 30 d later with LCMV (right). (A) Kinetic 
analysis of antigen-specific response to secondary infection. (B) KLRG1 
and CD127 expression at the peak of infection after rechallenge. Num-
bers are the percentage of the population in total antigen-specific CD8+ T 
cells from a representative mouse. (C) Quantification of the frequency of 
antigen-specific CD8+ T cell populations represented in B. Data are repre-
sentative of two independent experiments with n = 2–4. Mean ± SEM is 
shown. Unpaired, two-tailed Student’s t test was performed to determine 
significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 4. Microarray analysis of ZEB2-deficient CD8+ T cells. (A) Vol-
cano plot comparing differential gene expression between ZEB2-deficient 
and WT P14 cells. (B) Overlay of differential gene expression with ImmGen 
clusters II (orange), III (yellow), IV (green), and VII (blue; Best et al., 2013). 
(C) ChIP analysis performed with a ZEB2 antibody on OT-I cells on day 8 of 
Lm-OVA infection at E-boxes in the promoter and first intron of Il7r or in 
the proximal promoter and 2 kb upstream of Il2. Numbers in the bottom 
corners indicate the number of genes in that region. Data are from two 
independent experiments with three (A and B) or five (C) mice per group.
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tion (ChIP)–seq data that examined the E-box occupancy 
of E2A (and the bHLH factor EBF1) in B cells (Lin et al., 
2010) to cross reference against the genes we identified to 
be differentially expressed in Zeb2+/+ and Zeb2−/− cells (not 
depicted). Although not all genes up- or down-regulated in 
Zeb2−/− CD8+ T cells were found to be potential E2A tar-
gets, many of the most differentially expressed did have pu-
tative E-box sites that could be bound by E2A. Of the 82 
genes expressed 1.5-fold higher by Zeb2−/− cells, 13 were 
found to be E2A targets, and of the 200 genes expressed 1.5-
fold higher by WT cells, 21 were found to be E2A targets. 
These potential E-protein target genes that are differentially 
expressed by ZEB2−/− and WT cells include Ctse, Cx3cr1, 
Zeb2 itself, Nsg2, Il7r, Tcf7, and Cxcr5 and suggest that at 
least a subset of ZEB2-regulated genes in CD8+ T cells are 
also E-protein targets.
ZEB2 could act directly or indirectly to turn off genes 
necessary for the formation of terminally differentiated ef-
fector cells and shorter-lived KLRG1hi effector memory cells 
during infection. This places ZEB2 at a potential branch point 
of two effector lineages early in a response: the shorter-lived ef-
fector cells, which express low levels of CD127 and IL-2 and 
high levels of KLRG1 and make up the bulk (up to 90%) of 
the CD8+ T cell response, versus the memory precursor effec-
tor cells, which have effector function and contain cells that 
will seed the long-lived memory T cell population. To estab-
lish whether differentially expressed genes were directly reg-
ulated by ZEB2, we examined individual genes that contain 
potential ZEB2-binding sites (bipartite E-box sites [Remacle 
et al., 1999]) by ChIP. As analysis of the ZEB2-deficient CD8+ 
T cell populations revealed increased levels of CD127 expres-
sion (see also Fig. 3 A), we hypothesized that ZEB2 may be 
directly repressing the Il7r gene. Consistent with this, we find 
that anti-ZEB2–precipitated chromatin was indeed enriched 
for sequences in the Il7r promoter and introns, which con-
tain bipartite E-box sites (Fig. 4 C). It has been previously 
published that there are regulatory binding sites for ZEB1, 
which contain remarkable DNA-binding domain similar-
ity to ZEB2, in the Il2 gene that can mediate repression of 
Il2 expression (Williams et al., 1991; Yasui et al., 1998). Our 
analysis indicates that ZEB2 occupies these sites in activated 
CD8+ T cells (Fig. 4 C). Thus, it appears that ZEB2 may share 
targets with its homologue ZEB1 and could be responsible 
for the diminished production of IL-2 by KLRG1hi effector 
memory cells (Joshi et al., 2007; Sarkar et al., 2008).
Zeb2 is a target of T-bet
Our data show that ZEB2 is key in CD8+ effector T cell dif-
ferentiation and is likely part of a larger regulatory network. 
Interestingly, the T-box–binding transcription factor, T-bet, 
has also been shown to promote KLRG1hi effector cell dif-
ferentiation (Joshi et al., 2007). T-bet protein levels were not 
notably affected by the absence or overexpression of ZEB2 
in this system (Fig. 5 A and not depicted), suggesting that, if 
they are in the same transcriptional pathway, T-bet is likely 
upstream of ZEB2. In line with this, antigen-specific CD8+ T 
cells heterozygous for Tbx21 (Tbx21+/−) isolated on day 7 of 
Lm-OVA infection showed lower Zeb2 mRNA levels com-
pared with those expressing WT levels of T-bet. Upon exam-
ination of the regulatory regions of the Zeb2 gene, we found 
numerous, highly conserved predicted T-box sites upstream 
of the transcriptional start sight and in the 3′ untranslated 
region (UTR)–coding region of Zeb2, suggesting that T-bet 
could directly regulate Zeb2 expression. To address this, we 
performed ChIP analysis on WT bulk or KLRG1hiCD8+ T 
cells isolated on day 8 of infection with LCMV. We found that 
T-bet–precipitated chromatin was enriched for sequences in 
sites 5′ to the Zeb2 coding sequence and in the 3′ UTR and 
that this binding was lost in Tbx21−/− cells (Fig. 5 C). Thus, 
our data place ZEB2 downstream of T-bet in the regulation of 
gene expression, promoting the differentiation of KLRG1hi 
effector CD8+ T cells.
To further investigate the relationship between T-bet and 
ZEB2, we used microarray analysis of Tbx21+/+ and Tbx21−/− 
CD8+ T cells at day 6 of infection and compared global ex-
pression differences to genes differentially expressed between 
Zeb2+/+ and Zeb2−/− effector CD8+ T cells identified above 
(Fig.  4  A). Many genes were similarly regulated in the two 
comparisons (Fig. 5 D; R = 0.308). Consistent with the no-
tion that T-bet is upstream of ZEB2 activity, T-bet expression 
was not elevated in ZEB2-deficient versus WT CD8+ T cells. 
Furthermore, when we focused on genes up-regulated in 
Tbx21−/− CD8+ T cells compared with their WT counterparts, 
75% of those genes were also up-regulated by Zeb2−/− CD8+ 
T cells compared with their WT counterparts (Fig. 5 E, top). 
Similarly, of genes with lower expression in Tbx21−/− cells, 75% 
were also down-regulated in Zeb2−/− cells compared with WT 
cells (Fig. 5 E). These data suggest that a large subset of T-bet–
regulated genes are also regulated by ZEB2, whereas 25% of 
the T-bet–regulated gene expression program is independent of 
ZEB2 activity. Conversely, we see that 100% of genes up-reg-
ulated with loss of ZEB2 were correspondingly up-regulated 
in T-bet−/− T cells and 85% of the genes down-regulated with 
loss of ZEB2 were also down-regulated by Tbx21−/− T cells 
(Fig.  5  E, bottom), again indicating that T-bet may regulate 
ZEB2-dependent and -independent gene expression and that 
ZEB2-dependent genes are largely T-bet dependent.
Haploinsufficiency of ZEB2 does not affect 
peripheral T cell populations
Upon examination of the Zeb2+/− mice, we found they exhibit 
a modest accumulation defect compared with the Zeb2−/− 
mice after infection with VSV-OVA (Fig. 6 A), with a trend 
toward a loss of KLRG1hi effector CD8+ T cells at the peak of 
infection (Fig. 6 B). To see whether this translates to a human 
phenotype, we examined Mowat–Wilson syndrome (MWS) 
patients, who display a rare disorder resulting in facial dysmor-
phism, congenital heart disease, and lack of innervation of the 
lower bowel caused by haploinsufficiency of the Zeb2 gene 
(Mowat et al., 1998). To our knowledge, the peripheral im-
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mune status of these patients has not been examined. Here, we 
analyzed peripheral blood lymphocytes of five MWS patient 
with confirmed Zeb2 mutations. Compared with controls, the 
frequency of the CD4+ and CD8+ T cells appeared unaffected, 
whereas a trend toward a reduced percentage of CD19+ B 
cells was observed (Fig. 6, C and D). Furthermore, we noted 
minimal differences in the KLRG1 and CD127 CD8+ T cell 
populations between the MWS and control peripheral blood 
samples (Fig. 6 E). To further examine whether the CD8+ T cell 
differentiation defect extends from our Zeb2+/− mouse model 
to haploinsufficient human patients, we characterized the naive 
(CCR7+CD45RA+), central memory (CCR7+CD45RA−), 
effector memory (CCR7−CD45RA−), and CD45RA+ effec-
tor memory (CCR7−CD45RA+) CD8+ T cells in the blood. 
Again, we observed similar representation of all populations 
between MWS patients and controls (Fig. 6 F). These results 
suggest that haploinsufficiency of Zeb2 in humans is not suffi-
cient to manifest CD8+ T cell defects despite adversely affect-
ing other systems (Garavelli and Mainardi, 2007).
DIS CUSSI ON
Recent studies have revealed numerous transcriptional regula-
tors that govern formation of terminal effector versus memory 
CD8+ T cell populations (Kaech and Cui, 2012). Many of these 
factors are expressed in a gradient within the differentiating 
CD8+ T cell effector population, but when their expression is 
lost they prove to be key in supporting either effector or mem-
ory fates, raising the question as to how small differences in 
expression of transcription factors can enforce distinct differ-
entiation programs. Notably, ZEB2 is expressed almost exclu-
sively in the KLRG1hi terminally differentiated effector and 
effector memory populations. This correlation of ZEB2 ex-
pression with degree of differentiation has also been reported 
in human memory T cell subsets (Gattinoni et al., 2011) and 
observed in a profile of repetitively stimulated mouse memory 
CD8+ T cells (Wirth et al., 2010). Here, we describe a novel 
role for the transcriptional repressor ZEB2 in regulating the 
differentiation of CD8+ T cells responding to infection, plac-
ing its activity in the transcriptional network that represses the 
Figure 5. T-bet is upstream of ZEB2 in terminally dif-
ferentiating CD8+ T cells. (A) T-bet expression in ZEB2-de-
ficient and -sufficient P14 cells at day 8 of LCMV infection 
(top) and in CD44hiCD8+ T cells with (Zeb2Tg/+) or without 
(Zeb2+/+) constitutive ZEB2 expression (bottom). (B) T-bet and 
ZEB2 expression in Tbx21+/+ and Tbx21+/− OT-I T cells isolated 
at day 8 after Lm-OVA infection, as assessed by qPCR. (C) 
ChIP analysis was performed with a T-bet antibody on bulk 
or KLRG1hiCD8+ T cells isolated on day 8 of LCMV infection 
at the indicated sites 5′ to the Zeb2 coding sequence and 
in the 3′ UTR. Tbx21−/− splenocytes were used as a negative 
control. (D) Comparison of gene expression in Tbx21−/− versus 
Tbx21+/+ CD8+ OT-I T cells at day 6 after Lm-OVA infection, 
plotted against that for Zeb2−/− versus WT CD8+ P14 T cells 
at day 6 after LCMV infection. Gray lines indicate 1.5-fold 
cut-off. (E) Volcano plots comparing differential gene expres-
sion between ZEB2-deficient and WT P14 cells overlaid with 
those genes highly up-regulated (>1.5 fold) in Tbx21−/− (top 
left) or Tbx21+/+ (top right) OT-I cells or comparing differ-
ential gene expression between Tbx21−/− and Tbx21+/+ OT-I 
cells overlaid with those highly up-regulated (>1.5 fold) in 
Zeb2−/− (bottom left) or Zeb2+/+ (bottom right). Data are from 
two (A and C) or four (B) independent experiments, with n 
= 2–5. Microarray analysis represents two to three indepen-
dent replicates with n = 3.
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memory program and promotes terminal differentiation. In the 
absence of ZEB2, we see a dramatic reduction in the number of 
CD8+ T cells responding to primary and secondary infection, 
which can be accounted for by a loss of the KLRG1hiCD127lo 
subset, consistent with high ZEB2 expression. Additionally, we 
find that expression of genes associated with naive, memory, and 
memory precursor cells is enhanced when ZEB2 is absent, sug-
gesting ZEB2 functions to repress the memory program in ef-
fector CD8+ T cells. Our data highlight a previously undefined 
role for ZEB2 in the cell fate decision of effector CD8+ T cells.
We place ZEB2 as a downstream target of T-bet in the reg-
ulatory network that promotes the formation of the KLRG1hi 
terminally differentiated subset of activated CD8+ T cells. 
Our microarray analysis shows ZEB2-mediated gene expres-
sion patterns are largely overlapping with those regulated by 
T-bet. Our ChIP analysis confirms that T-bet binds sites both 
5′ to the coding sequence and in the 3′ UTR–coding region 
of Zeb2 and thus may directly impact expression of Zeb2 
in the context of infection. T-bet protein is expressed in a 
gradient across effector CD8+ T cell populations with the 
highest amounts observed in KLRG1hi shorter-lived effector 
cells and twofold lower levels in memory precursor effector 
cells (Takemoto et al., 2006; Joshi et al., 2007). Elevated lev-
els in KLRG1hi shorter-lived effector cells may allow for in-
creased T-bet–mediated gene expression, including induction 
of ZEB2 expression itself. In the absence of T-bet, a similar 
but more dramatic phenotype to that of ZEB2 deficiency is 
observed with a reduced accumulation of effector CD8+ T 
cells after infection and an almost complete lack of terminally 
differentiated effector CD8+ T cells (Joshi et al., 2007). This 
fits with the notion that T-bet mediates a gene expression 
program that largely involves cooperation of ZEB2 but that 
also includes ZEB2-independent targets.
We propose that ZEB2 may also act in concert or par-
allel to Id2 to regulate the transcriptional program of KL-
RG1hiCD8+ T cells. Id2 is expressed in both the KLRG1hi 
Figure 6. Heterozygotic mutation of ZEB2 in MWS patients 
does not affect T cell populations of the blood. (A) Zeb2+/+, 
Zeb2+/−, and Zeb2−/− T cell kinetics were monitored after VSV-
OVA infection. The frequency of endogenous CD8+tetramer+ cells 
in the CD8+ PBL population is shown. (B) Quantification of the 
frequency of antigen-specific KLRG1 and CD127 CD8+ T cell pop-
ulations on day 8 at the peak of infection. Data are representa-
tive of five independent replicates with n = 3–6. (C) CD4+ T cell, 
CD8+ T cell, and CD19+ B cell populations in the blood of MWS 
patients and WT controls. (D) Quantification of the frequency of 
populations represented in C. (E) KLRG1 and CD127 expression on 
CD8+ T cell populations of MWS patients and controls. (F) Analy-
sis of naive (CCR7+CD45RA+), central memory (CCR7+CD45RA−), 
effector memory (CCR7−CD45RA−), and CD45RA+ effector mem-
ory (CCR7−CD45RA+) CD8+ T cells in the blood of MWS patients 
and controls. Numbers in contour plots are the percentage of the 
indicated population of a representative sample. Data are pooled 
from two independent experiments with n = 5–6. Mean ± SEM 
is shown. Unpaired, two-tailed Student’s t test was performed 
to determine significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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and KLRG1lo effector subsets. Similar to ZEB2, Id2 is nec-
essary for the survival and differentiation of mature CD8+ T 
cell as CD8+ T cells lacking Id2 do not generate a terminally 
differentiated effector population (Cannarile et al., 2006; Yang 
et al., 2011; Knell et al., 2013) The mechanisms of ZEB2 and 
Id2 likely allow for overlapping but not necessarily identical 
regulation. Id proteins have no DNA-binding domain but 
rather bind E-proteins and prevent them from binding their 
gene targets (Massari and Murre, 2000; Engel and Murre, 
2001), whereas ZEB2 is able to compete with E-proteins to 
bind DNA (Sekido et al., 1994; Remacle et al., 1999). Ad-
ditional selectivity may be garnered by slight variations in 
sequences bound by ZEB2 and E-proteins. E-proteins, in 
general, bind a canonical CAN NTG (Murre et al., 1989; 
Engel and Murre, 2001), whereas ZEB2 more specifically 
binds a bipartite repeat of the CAC CT(G), often referred to 
as an E2-box, suggesting regulation of a smaller, more specific 
subset of E-protein target genes. KLRG1hiCD8+ T cells may 
be more sensitive to E-protein activity than their memory 
precursor counterparts and require the dual inhibitory action 
of both Id2 and ZEB2 for development.
One important question is what are the direct targets 
of ZEB2? ZEB2 likely mediates some of its regulation by 
binding to E-box sites in target genes. We find that a portion 
of genes showing differential expression between Zeb2+/+ 
and Zeb2−/− CD8+ T cells are putative E2A targets. Specifi-
cally, we show an enrichment of E-boxes in both the Il2 and 
Il7r genes when we isolated DNA bound by ZEB2. IL-2 is 
expressed at lower levels in terminally differentiated effec-
tor CD8+ T cells than their memory precursor counterparts 
(Sarkar et al., 2008). ZEB2 may directly target Il2, providing 
an explanation for the inability of KLRG1hiCD8+ T cells to 
produce this cytokine as well as the increased responsiveness 
of this population to IL-2 (Rubinstein et al., 2008). Similarly, 
we find ZEB2 bound at proximal enhancers in the Il7r locus. 
Though not sufficient for memory precursor formation, 
CD127 surface expression correlates with memory poten-
tial during infection. In the secondary response, ZEB2-defi-
cient T cells are capable of up-regulating KLRG1 but do not 
down-regulate CD127. Thus, ZEB2 may function to inhibit 
the expression of Il7r in terminally differentiated effector 
CD8+ T cells. Notably, a recent study also provides evidence 
for ZEB2-mediated regulation of Il7r expression (Goossens 
et al., 2015). In this instance, ZEB2 expression in early T cell 
development initiated T cell leukemia via activation of the 
JAK/STAT signaling pathway downstream of elevated Il7r 
mRNA expression, and blockade of CD127 impaired tumor 
survival and growth, indicating an essential role for IL-7–me-
diated signaling in this model (Goossens et al., 2015). The role 
of ZEB2 as a driver of, as opposed to a repressor of, Il7r ex-
pression may be the result of additional factors that ZEB2 as-
sociates with (and additional posttranslational modification of 
components in the ZEB2 complex) in different cell types or 
differentiation stages or as a result of a transformation event. 
In addition to binding E-boxes, ZEB2 is able to bind activated 
Smads and mediate suppression of Smad targets (Verschueren 
et al., 1999). The role of Smad-mediated ZEB2 repression in 
CD8+ T cell differentiation will be the focus of future studies.
Here we provide evidence that ZEB2 is essential in the 
generation of the CD8+ T cell response to infection and is nec-
essary for accumulation of terminally differentiated effector 
CD8+ T cells. Our data support the finding that ZEB2 expres-
sion is downstream of T-bet and is most highly induced during 
infection and after repetitive antigen stimulation (Wirth et al., 
2010). This places ZEB2 as one of the key regulators of effec-
tor CD8+ T cell terminal differentiation and highlights a key 
fate decision point in the formation of CD8+ T cell memory. 
The function of ZEB2 in regulating terminal differentiation of 
CD8+ T cells, similar to other systems (see Conidi et al. [2011]), 
and the fact that it is a zinc-finger–containing transcription 
factor make it an interesting and specific therapeutic target as 
has been shown for other zinc-finger transcription factors, in-
cluding the Snail family (Rice et al., 1997; Harney et al., 2009, 
2012; Larabee et al., 2009). Furthermore, these data help foster 
a basal understanding of the mechanisms of memory forma-
tion, providing insight that may inform future vaccine design.
MAT ERIALS AND MET HODS
Mice. Mice with a loxP-flanked ZEB2 allele were a gift of 
D. Huylebroeck (Higashi et al., 2002). These mice were orig-
inally derived on the outbred Swiss CD-1 background and 
were backcrossed >10 times to C57BL/6J mice to achieve 
99.9% similarity, as verified by GenCheck Speed Congenics 
services (Harlan Laboratories, Inc.). Mice were crossed to the 
CD4-cre recombinase strain (Sawada et al., 1994) and subse-
quently to either OT-I or P14 transgenic lines. WT litter-
mates were used for controls.
For microarray experiments, male C57BL/6J mice 
were obtained from the Jackson Laboratory and housed in 
specific pathogen–free conditions for 7–10 d before experi-
mentation. All mice were bred and housed in specific patho-
gen–free conditions in accordance with the Institutional 
Animal Care and Use Guidelines of the University of Cali-
fornia, San Diego (UCSD).
Human experiments. After obtaining informed consent under 
a Human Research Protections Program–UCSD-approved 
protocol and from the ethics committee of the Medical Fac-
ulty at the University of Erlangen-Nuremberg, whole blood 
samples were obtained from five patients suffering from 
MWS and six healthy controls. Two patients have been previ-
ously published (Zweier et al., 2002).
Quantitative PCR (qPCR). RNA was extracted using TRIzol 
reagent (Life Technologies), and cDNA was reverse transcribed 
with a Superscript III First-Strand Synthesis kit (Life Technol-
ogies). qPCR was performed using Stratagene Brilliant II Sybr 
Green master mix (Agilent Technologies). Quantities of tran-
script were normalized to GAP DH levels. The following prim-
ers were used: ZEB2, 5′-CAT GAACC CATTT AGTGC CA-3′ 
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and 5′-AGC AAGTC TCCCT GAAAT CC-3′; T-bet, 5′-AGC 
AAGGA CGGCG AATGTT-3′ and 5′-GTG GACAT ATAAG 
CGGTT CCC-3′; and GAP DH, 5′-CCA GTATG ACTCC 
ACTCA CG-3′ and 5′-GAC TCCAC GACAT ACTCA GC-3′.
Infection. Mice were infected intravenously with 5 × 103 
CFU recombinant Lm-OVA or Lm-gp33 or infected intra-
peritoneally with 105 PFU recombinant VSV-OVA or 2 × 105 
PFU LCMV-Armstrong. For adoptive transfer experiments, 5 
× 103 CD45.1+ OT-I or P14 ZEB2−/− and CD45.1.2+ OT-I 
or P14 ZEB2 WT cells were singly or co-transferred (1:1 
ratio) into CD45.2+ C57BL/6J recipients 1 d before infec-
tion. For secondary infections, mice were rechallenged intra-
venously with 5 × 104 CFU (for VSV-OVA primary 
infections) or intraperitoneally with 5 × 104 Lm-gp33 (for 
LCMV primary infections).
Flow cytometry. Single-cell suspensions were prepared from 
spleen, lymph node, liver, lung, or blood. The following anti-
bodies were used (all from eBioscience unless specified other-
wise): CD8 (53-6.7), CD27 (LG-7F9), CD44 (IM7), CD45.1 
(A20-1.7), CD45.2 (104), CXCR3 (CXCR3-173), T-bet 
(eBio4B10), CD43 (1B11), CD127 (A7R34), KLRG1 (2F1), 
IL-2 (JES6-5H4), and IFN-γ (XMG1.2). Antigen-specific 
CD8+ T cells were identified with H-2Kb–OVA (SII NFEKL) 
or H-2Db–gp33 (KAV YNFATC) tetramer (Beckman Coulter). 
For intracellular cytokine staining, splenocytes were incubated 
for a total of 6 h at 37°C at a density of 4 × 106 cells per well 
in RPMI-1640 media (Corning) containing 10% (vol/vol) bo-
vine growth serum (Life Technologies) with 10 nM gp33 pep-
tide. After 2 h, GolgiStop Transport Inhibitor (BD) was added 
and cultures were incubated for an additional 4 h. Cells were 
collected and stained with antibodies to surface molecules, 
fixed and permeabilized using the Cytofix/Cytoperm Fixa-
tion/Permeabilization kit (BD), and then stained intracellularly. 
For analysis of in vivo proliferation, 1 mg BrdU was injected 
intraperitoneally into mice, and 4  h later splenocytes were 
stained using the BrdU Flow kit (BD). For analysis of cell via-
bility, splenocytes were stained with Annexin V and 7-ami-
no-actinomycin D (7AAD; Life Technologies) according to the 
manufacturer’s protocol. Cells were analyzed by flow cytome-
try within 1 h. For human blood samples, leukocytes were pu-
rified using Histopaque (Sigma-Aldrich) and stained with the 
following antibodies (all from BD unless specified otherwise): 
CD4 (L200), CD8 (SK1; eBioscience), CD19 (HIB19; eBiosci-
ence), CD27 (M-T271), CD45RA (HI100), CD127 (HIL-
7R-M21), and CCR7 (3D12). Samples were collected on a 
FAC SCalibur, FACS LSRFortessa, or FAC SAria (BD) and an-
alyzed with FlowJo software (Tree Star).
ChIP. 4.0 × 107 CD8+ T cells were FACS sorted from spleno-
cytes prepared from mice infected for 8 d with Lm-OVA, fixed 
in 1% formaldehyde for 10 min, and subsequently quenched by 
adding glycine to a final concentration of 0.125 M. Cells were 
lysed in buffer (1% SDS, 10 mM EDTA, pH 8, and 50 mM 
Tris-HCL, pH 8) and then sonicated to generate ∼250–750-bp 
fragments. Immunoprecipitation was performed with 5 µg an-
tibody (Seuntjens et al., 2009) on 10 µg DNA and allowed to 
rotate overnight at 4°C. 30 µl protein F agarose beads (Cell 
Signaling Technology) were then added and allowed to rotate 
for 2 h at 4°C. Beads were spun, washed, and eluted according 
to the Cell Signaling Technology protocol. DNA was reverse 
cross-linked overnight at 65°C and then treated for 30 min at 
37°C with RNase, followed by 2 h at 55°C with Proteinase K. 
qPCR was performed using Stratagene Brilliant II Sybr Green 
kit (Agilent Technologies). Primer sets used were Il7ri, 5′-TGC 
TTAGA TGCTT CCTAT TGAA-3′ and 5′-TTG CACAG 
AGGTT TCATT TAC-3′; IL7rp, 5′-TCC CGCAC TCTAT 
TTAGA TTTC-3′ and 5′-TCA TTTAA GTGGA CCATC 
ATTT-3′; IL22kb, 5′-CAT GCAGA GAGTT TTTTG TTGTT 
GTTTT CTAG-3′ and 5′-GCC TAAAG TCTCT CACAA 
AGAAC AGA-3′; IL2prox, 5′-CAC AGGTA GACTC TTTGA 
AAATA TGTGT AA-3′ and 5′-CAT GGGAG GCAAT TTATA 
CTGTT AATG-3′; Tbx1, 5′-ACC AAATC AGACC ACGAG 
GA-3′ and 5′-ACT CTGTC TTGGC TGAAC TGC-3′; and 
Tbx3, 5′-TTG AAGCA CCCGT GTCAG TA-3′ and 5′-TGA 
CCTAA AATTA AATGA ATGCA AAA-3′.
Microarray analysis. CD8+CD45.1.2+ (Zeb2−/−) or 
CD8+CD45.2+ (Zeb2+/+) P14 transgenic T cells were sorted 
into TRIzol reagent from three pooled mice 6 d after LCMV 
infection. CD8+CD45.1+ (T-bet−/−) and CD8+CD45.2+ (T-
bet+/+) OT-I transgenic T cells were similarly sorted from 
three pooled mice 6 d after Lm-OVA infection. RNA was 
amplified and hybridized to the Mouse Gene 1.0 ST Array 
(Affymetrix). Microarray analysis was performed using the 
GenePattern suite and R. Using the ImmGen Project profil-
ing and quality control (QC) pipelines, gene expression pro-
files were generated on Mouse Gene 1.0 ST arrays. All data 
analyzed passed ImmGen QC, with good replicate quality. 
The general ImmGen postnormalization threshold of 120 
was taken to indicate positive expression (at 95% confidence), 
and probes were included in comparisons only if they were 
expressed by at least one cell type and with low variability 
within populations (CV < 0.5). The microarray data are de-
posited in the GEO database under accession no. GSE72162.
Online supplemental material. A list of genes with differential 
gene expression between ZEB2-deficient and -sufficient P14 
CD8+ T cells on day 6 after LCMV infection can be found in 
Table S1. Online supplemental material is available at http ://
www .jem .org /cgi /content /full /jem .20150194 /DC1.
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